Acriflavine directly binds to DNA-PKcs and inhibits its kinase activity particularly.
Acriflavine enhances the DNA damage caused by melphalan and exerts synergistic efficacy with melphalan against cancer cells.
The p53 status dictated the cell fate in response to the combination therapy.